BD Launches AI-Powered Hemodynamic Monitoring Platform to Improve Critical Care Outcomes

Becton, Dickinson and Company (NYSE: BDX) has introduced HemoSphere Alta, its most advanced hemodynamic monitoring platform, featuring AI-driven clinical decision support tools designed to help clinicians anticipate and manage blood pressure instability in critical care settings.

The system integrates smart algorithms, including the newly developed Cerebral Autoregulation Index (CAI), a breakthrough parameter that helps determine whether a patient's brain can maintain stable blood flow under fluctuating blood pressure. When used in combination with the noninvasive ForeSight IQ and invasive Acumen IQ sensors, CAI offers personalized insights into cerebral perfusion needs.

HemoSphere Alta also includes BD's Acumen Hypotension Prediction Index (HPI), which has been validated in large studies for its ability to forecast hypotensive events before they occur, allowing clinicians to intervene sooner and potentially reduce the risk of organ damage or death.

The platform features a redesigned user interface with a 15-inch customizable touchscreen, split-screen display options, and voice and gesture controls to streamline workflows and maintain sterility in surgical environments.

“This platform combines predictive analytics with real-time monitoring to give clinicians unprecedented visibility into patient stability,” said Tim Patz, president of BD Advanced Patient Monitoring. “It’s a major step forward in enabling personalized, precision-guided hemodynamic care.”

The launch follows BD’s acquisition of Advanced Patient Monitoring and reinforces its commitment to developing connected care technologies that harness AI and data science to enhance clinical decision-making and patient safety.